Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?

× No keyword cloud information.

7 in total

1. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.

Authors: G Caocci; F Murgia; L Podda; A Solinas; S Atzeni; G La Nasa
Journal: Leukemia Date: 2013-08-09 Impact factor: 11.528

Review 2. A journey through infectious risk associated with ruxolitinib.

Authors: Emanuela Sant'Antonio; Massimiliano Bonifacio; Massimo Breccia; Elisa Rumi
Journal: Br J Haematol Date: 2019-08-29 Impact factor: 6.998

3. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.

Authors: Asra Ahmed; Samuel A Merrill; Fares Alsawah; Paula Bockenstedt; Erica Campagnaro; Sumana Devata; Scott D Gitlin; Mark Kaminski; Alice Cusick; Tycel Phillips; Suman Sood; Moshe Talpaz; Albert Quiery; Philip S Boonstra; Ryan A Wilcox
Journal: Lancet Haematol Date: 2019-09-16 Impact factor: 18.959

Review 4. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

Authors: Cecilia Arana Yi; Constantine S Tam; Srdan Verstovsek
Journal: Future Oncol Date: 2015 Impact factor: 3.404

5. Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis.

Authors: Amélie Seguin; Lionel Galicier; David Boutboul; Virginie Lemiale; Elie Azoulay
Journal: Chest Date: 2016-01-13 Impact factor: 9.410

6. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.

Authors: Qiurong Ruan; Kun Yang; Wenxia Wang; Lingyu Jiang; Jianxin Song
Journal: Intensive Care Med Date: 2020-03-03 Impact factor: 17.440

7. COVID-19: consider cytokine storm syndromes and immunosuppression.

Authors: Puja Mehta; Daniel F McAuley; Michael Brown; Emilie Sanchez; Rachel S Tattersall; Jessica J Manson
Journal: Lancet Date: 2020-03-16 Impact factor: 79.321

7 in total

6 in total

1. TextEssence: A Tool for Interactive Analysis of Semantic Shifts Between Corpora.

Authors: Denis Newman-Griffis; Venkatesh Sivaraman; Adam Perer; Eric Fosler-Lussier; Harry Hochheiser
Journal: Proc Conf Date: 2021-06

Review 2. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19.

Authors: Joydeb Majumder; Tamara Minko
Journal: AAPS J Date: 2021-01-05 Impact factor: 4.009

Review 3. Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19.

Authors: Dingzhong Li; Jianbing Hu; Dian Li; Weijun Yang; Shuang-Feng Yin; Renhua Qiu
Journal: Top Curr Chem (Cham) Date: 2021-01-11

Review 4. The signal pathways and treatment of cytokine storm in COVID-19.

Authors: Lan Yang; Xueru Xie; Zikun Tu; Jinrong Fu; Damo Xu; Yufeng Zhou
Journal: Signal Transduct Target Ther Date: 2021-07-07

Review 5. Role of monoclonal antibody drugs in the treatment of COVID-19.

Authors: Claudio Ucciferri; Jacopo Vecchiet; Katia Falasca
Journal: World J Clin Cases Date: 2020-10-06 Impact factor: 1.337

6. Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis.

Authors: Giovanni Caocci; Olga Mulas; Daniela Mantovani; Alessandro Costa; Andrea Galizia; Luca Barabino; Marianna Greco; Roberta Murru; Giorgio La Nasa
Journal: Ann Hematol Date: 2021-07-24 Impact factor: 3.673

6 in total